Cellular Biomedicine Approved to Start China Stem Cell Trial
January 17, 2019 at 06:43 AM EST
Cellular Biomedicine, a Shanghai immunotherapy/stem cell company, reported that its off-the-shelf therapy for Knee Osteoarthritis (KOA) was approved to start a China Phase II trial. AlloJoin® is an allogeneic adipose-derived mesenchymal progenitor cell (haMPC) product. It is the first allogeneic stem cell drug application approved for a KOA Phase II clinical trial in China . In December 2017, the China NMPA declared that all cell therapies must comply with the drug IND/NDA process. The AlloJoin IND was approved after a 60-day priority review. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //
